Sign inJoin waitlistJoin the waitlist

Amna Sher

Assistant Professor of Medicine · Stony Brook Medicine

Credentials: · · · · · ·

History

Stony Brook Medicine
Present

Hematology and Medical Oncology
2008–2011
Stony Brook Medicine
2005–2008
Doctor of Medicine
2001–2005

Research

Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis
Systematic review or meta-analysis · Oncology · 2010 · 141 citations
Fatal Adverse Events Associated with Pembrolizumab in Cancer Patients: A Meta-Analysis
Systematic review or meta-analysis · Cancer Investigation · 2020 · First of 3 authors · 19 citations
Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis
Systematic review or meta-analysis · Acta Oncologica · 2011 · First of 2 authors · 13 citations

Shenhong Wu
3 papers
Asim Khokhar
1 paper
GG
Gol Golshani
1 paper · 1 as a fellow
MS
Mark Schattner
1 paper
Roger Keresztes
1 paper
SH
Sanjaykumar Hapani
1 paper · 1 as a fellow
Sowmini Medavaram
1 paper · 1 as a fellow

Clinical trials

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2027–2032
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2039
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2021–2029
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2020–2027